TuisNOTA • FRA
add
Novartis
Vorige sluiting
€141,00
Dagwisseling
€137,50 - €137,50
Jaarwisseling
€88,20 - €140,50
Markkapitalisasie
350,84Â mjd USD
Gemiddelde volume
99,00
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 13,86Â mjd | 2,23% |
Bedryfskoste | 6,46Â mjd | 30,83% |
Netto inkomste | 2,41Â mjd | -14,51% |
Netto winsgrens | 17,38 | -16,36% |
Wins per aandeel | 2,03 | 2,53% |
EBITDA | 4,96Â mjd | -22,64% |
Effektiewe belastingkoers | 25,30% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 11,53Â mjd | -13,62% |
Totale bates | 110,95Â mjd | 8,51% |
Totale aanspreeklikheid | 64,40Â mjd | 10,81% |
Totale ekwiteit | 46,55 mjd | — |
Uitstaande aandele | 1,91 mjd | — |
Prys om te bespreek | 5,83 | — |
Opbrengs op bates | 8,83% | — |
Opbrengs op kapitaal | 12,14% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 2,41Â mjd | -14,51% |
Kontant van bedrywe | 2,26Â mjd | -46,01% |
Kontant van beleggings | -2,10Â mjd | 30,63% |
Kontant van finansiering | 1,68Â mjd | 156,17% |
Netto kontantverandering | 1,88Â mjd | 187,40% |
Beskikbare kontantvloei | -177,62Â m | -104,78% |
Meer oor
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Gestig
29 Feb. 1996
Hoofkwartier
Webwerf
Werknemers
75Â 267